Clinical Trials
113 trialsNCT05256225 2026-05-27
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT05564377 2026-05-27
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07198074 2026-05-27
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT06607185 2026-05-26
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
NCT07061977 2026-05-26
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT01167712 2026-05-04
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02446600 2026-05-04
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03914612 2026-05-04
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT01081262 2026-04-30
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT00977574 2026-04-29
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02502266 2026-04-29
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT04615013 2026-04-16
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT04220827 2026-04-15
Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05039801 2026-04-15
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT01366144 2026-04-13
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03587311 2026-04-13
Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04739800 2026-04-13
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04095364 2026-03-24
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NRG Oncology
Phase 3 Active not recruiting
NCT01970722 2026-03-05
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT04781088 2026-02-11
Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT05415709 2026-02-11
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer
Ohio State University Comprehensive Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT05092373 2026-01-14
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT00565851 2025-12-30
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT05276973 2025-12-19
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02726997 2025-12-18
Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT02364713 2025-12-11
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
Mayo Clinic
Phase 2 Terminated
NCT05383482 2025-11-17
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
Laekna Limited
Phase 1/2 Completed
NCT05092360 2025-08-28
ARTISTRY-7
Mural Oncology, Inc
Phase 3 Terminated
NCT06492070 2025-08-27
Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
Emory University
Phase 2 Recruiting
NCT06543576 2025-08-15
External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer
Jonsson Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT04055649 2025-06-18
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Recruiting
NCT02520154 2025-06-08
Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT05044871 2025-06-08
BRIGHT
Tongji Hospital
Phase 2 Completed
NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT06393751 2025-06-03
Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
NCT02713386 2025-05-25
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NRG Oncology
Phase 1/2 Completed
NCT02684227 2025-03-19
Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04906382 2025-02-13
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
Ohio State University Comprehensive Cancer Center
Phase EARLY_PHASE1 Terminated
NCT04731467 2024-12-27
A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors
Purple Biotech Ltd.
Phase 1/2 Completed
NCT02312245 2024-12-05
Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Mayo Clinic
Phase 2 Completed
NCT06289062 2024-11-05
Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer
Tongji Hospital
Phase 2 Recruiting
NCT06288373 2024-10-30
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
Tongji Hospital
Phase 2/3 Recruiting
NCT02020707 2024-07-26
Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
Mayo Clinic
Phase 1 Completed
NCT03719326 2024-05-24
A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies
Arcus Biosciences, Inc.
Phase 1 Completed
NCT04000906 2024-05-24
Nab-PIPAC
University Hospital, Geneva
Phase 1 Active not recruiting
NCT06426056 2024-05-23
Nab-Paclitaxel Plus Cisplatin With Concurrent Radiotherapy for Patients With Locally Advanced Cervical Cancer: A Multicentre, Single-arm, Phase II Trial.
Peking University Third Hospital
Phase 2 Not yet recruiting
NCT06413992 2024-05-14
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT01962948 2024-03-26
Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Fox Chase Cancer Center
Phase 1/2 Terminated
NCT02923739 2024-03-13
Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn